BMS-470539 is a small-molecule experimental drug which acts as a potent and highly selective full agonist of the MC1 receptor. It was discovered in 2003 as part of an effort to understand the role of the MC1 receptor in immunomodulation, and has since been used in scientific research to determine its role in inflammatory processes. The compound was designed with the intention of mimicking the central His-Phe-Arg-Trp pharmacophore of the melanocortins, and this proved to be successful based on its favorable pharmacodynamic profile. See also Afamelanotide Bremelanotide Melanotan II Modimelanotide Setmelanotide References Carboxamides Anti-inflammatory agents Imidazoles Immunomodulating drugs Melanocortin receptor agonists 4-Phenylpiperidines